SCHEMBL2198484

SCHEMBL2198484

COc1ccc(C(=O)NCCCO)cc1C(=O)c1ccc(Nc2c(F)cccc2F)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.46
HDAC6 Q9UBN7 1/20 0.43
MAPK13 O15264 1/20 0.43
MAPK12 P53778 1/20 0.43
MAPK11 Q15759 1/20 0.43
MAPK14 Q16539 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MAPT P10636 2/20 0.42
HPGD P15428 1/20 0.42
BCL6 P41182 2/20 0.41
PDE4D Q08499 3/20 0.41
MRGPRX4 Q96LA9 1/20 0.41
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
DRD3 P35462 1/20 0.40
KDM4E B2RXH2 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2199380 0.95 MAPK13 (0.44) POLBHDAC6MAPK13MAPK12MAPK11
SCHEMBL2197429 0.91 MAPK13 (0.44) HDAC6MAPK13MAPK12MAPK11MAPK14
SCHEMBL2202440 0.88 NPC1 (0.53) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL2198948 0.86 MAPK14 (0.42) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL6024057 0.85 MAPK13 (0.41) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL2571138 0.84 MAPT (0.49) POLBMAPK13MAPK12MAPK11MAPK14
SCHEMBL2197272 0.84 CD274 (0.56) POLBKMT2ASMN1; SMN2KDM4EALDH1A1
SCHEMBL2199863 0.84 MAPK13 (0.43) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL2197983 0.84 NPC1 (0.44) MAPK13MAPK12MAPK11MAPK14MEN1
SCHEMBL2198769 0.84 MAPK13 (0.49) POLBMAPK13MAPK12MAPK11MAPK14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP claimed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP claimed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US claimed
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 POLB 810/4885HDAC6 1690/4885MAPK13 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.